Similar, median OS in stromal CD34+ tumor patients (Fig 2c) was 1798 (95% CI: 1226.0–2370.0) days, while CD34‐negativity resulted in reduced median survival of 1068 (95% CI: 798.7–1337.3) days (P = 0.024). The gene discussed is CD34; the disease is neoplasm.